225 related articles for article (PubMed ID: 36609661)
1. Ubiquilin-2 regulates pathological alpha-synuclein.
Sandoval-Pistorius SS; Gerson JE; Liggans N; Ryou JH; Oak K; Li X; Negron-Rios KY; Fischer S; Barsh H; Crowley EV; Skinner ME; Sharkey LM; Barmada SJ; Paulson HL
Sci Rep; 2023 Jan; 13(1):293. PubMed ID: 36609661
[TBL] [Abstract][Full Text] [Related]
2. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
3. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
Henderson MX; Trojanowski JQ; Lee VM
Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies.
Kawahata I; Finkelstein DI; Fukunaga K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682892
[TBL] [Abstract][Full Text] [Related]
5. Disrupting the Balance of Protein Quality Control Protein UBQLN2 Accelerates Tau Proteinopathy.
Gerson JE; Sandoval-Pistorius S; Welday JP; Rodriguez A; Gregory JD; Liggans N; Schache K; Li X; Trzeciakiewicz H; Barmada S; Sharkey LM; Paulson HL
J Neurosci; 2022 Mar; 42(9):1845-1863. PubMed ID: 35082119
[TBL] [Abstract][Full Text] [Related]
6. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
[TBL] [Abstract][Full Text] [Related]
7. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.
Poehler AM; Xiang W; Spitzer P; May VE; Meixner H; Rockenstein E; Chutna O; Outeiro TF; Winkler J; Masliah E; Klucken J
Autophagy; 2014; 10(12):2171-92. PubMed ID: 25484190
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of astrocytic Ca
Nanclares C; Poynter J; Martell-Martinez HA; Vermilyea S; Araque A; Kofuji P; Lee MK; Covelo A
Acta Neuropathol; 2023 May; 145(5):597-610. PubMed ID: 36764943
[TBL] [Abstract][Full Text] [Related]
9. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.
Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M
Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925
[TBL] [Abstract][Full Text] [Related]
10. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.
Walker DG; Lue LF; Adler CH; Shill HA; Caviness JN; Sabbagh MN; Akiyama H; Serrano GE; Sue LI; Beach TG;
Exp Neurol; 2013 Feb; 240():190-204. PubMed ID: 23201181
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
[TBL] [Abstract][Full Text] [Related]
12. Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice.
Tanji K; Mori F; Mimura J; Itoh K; Kakita A; Takahashi H; Wakabayashi K
Acta Neuropathol; 2010 Aug; 120(2):145-54. PubMed ID: 20339856
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
14. Specific Detection of Physiological S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay.
Arlinghaus R; Iba M; Masliah E; Cookson MR; Landeck N
J Parkinsons Dis; 2023; 13(2):255-270. PubMed ID: 36847016
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
[TBL] [Abstract][Full Text] [Related]
16. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
Oueslati A
J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
[TBL] [Abstract][Full Text] [Related]
17. Pathological biochemistry of alpha-synucleinopathy.
Iwatsubo T
Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
[TBL] [Abstract][Full Text] [Related]
19. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
von Coelln R; Thomas B; Andrabi SA; Lim KL; Savitt JM; Saffary R; Stirling W; Bruno K; Hess EJ; Lee MK; Dawson VL; Dawson TM
J Neurosci; 2006 Apr; 26(14):3685-96. PubMed ID: 16597723
[TBL] [Abstract][Full Text] [Related]
20. Modeling UBQLN2-mediated neurodegenerative disease in mice: Shared and divergent properties of wild type and mutant UBQLN2 in phase separation, subcellular localization, altered proteostasis pathways, and selective cytotoxicity.
Sharkey LM; Sandoval-Pistorius SS; Moore SJ; Gerson JE; Komlo R; Fischer S; Negron-Rios KY; Crowley EV; Padron F; Patel R; Murphy GG; Paulson HL
Neurobiol Dis; 2020 Sep; 143():105016. PubMed ID: 32653673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
